Selective CDK inhibitors discriminating between cell cycle and transcriptional kinases: Future reality or utopia?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F09%3A00005287" target="_blank" >RIV/61989592:15310/09:00005287 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Selective CDK inhibitors discriminating between cell cycle and transcriptional kinases: Future reality or utopia?

Popis výsledku v původním jazyce

Progression of the cell cycle is controlled by activating and inhibiting cellular factors. The delicate balance between these positive- and negative-acting regulators warrants proper cell cycle progression in normal cells and facilitates cellular response to a variety of stress stimuli. The increased activity of the positive regulators of the cell cycle in cancer cells is frequently accompanied by the loss or inactivation of the inhibitors of cyclin-dependent kinases (CDKs). The supplementation of the cellular CDK inhibitors by the pharmacological counterparts is a very promising therapeutic option. The generated pharmacological inhibitors of CDKs belong to different classes of compounds and display various CDK inhibitory features. In this article theaction and specificity of CDK inhibitor roscovitine belonging to the group of purine analogues is reviewed and the rationale for dissecting of the inhibitory action on cell cycle and transcriptional CDKs is discussed.

Název v anglickém jazyce

Selective CDK inhibitors discriminating between cell cycle and transcriptional kinases: Future reality or utopia?

Popis výsledku anglicky

Progression of the cell cycle is controlled by activating and inhibiting cellular factors. The delicate balance between these positive- and negative-acting regulators warrants proper cell cycle progression in normal cells and facilitates cellular response to a variety of stress stimuli. The increased activity of the positive regulators of the cell cycle in cancer cells is frequently accompanied by the loss or inactivation of the inhibitors of cyclin-dependent kinases (CDKs). The supplementation of the cellular CDK inhibitors by the pharmacological counterparts is a very promising therapeutic option. The generated pharmacological inhibitors of CDKs belong to different classes of compounds and display various CDK inhibitory features. In this article theaction and specificity of CDK inhibitor roscovitine belonging to the group of purine analogues is reviewed and the rationale for dissecting of the inhibitory action on cell cycle and transcriptional CDKs is discussed.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CE - Biochemie

OECD FORD obor

—

Projekt

<a href="/cs/project/GA204%2F08%2F0511" target="_blank" >GA204/08/0511: Biologická aktivita syntetických inhibitorů cyklin-dependentních kinas</a><br>

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2009

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Annals of the New York Academy of Sciences

ISSN

0077-8923

e-ISSN

—

Svazek periodika

186

Číslo periodika v rámci svazku

1171

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

14

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—